Quantification of viral inactivation by photochemical treatment with amotosalen and UV a light, using a novel polymerase chain reaction inhibition method with preamplification

Journal of Infectious Diseases

Volumn 194, Issue 12, 2006, Pages 1737-1744

  Allain, Jean Pierre ^a   Hsu, Jocelyn ^b   Pranmeth, Manisha ^a   Hanson, Deborah ^b   Stassinopoulos, Adonis ^b,c   Fischetti, Lucia ^a   Corash, Laurence ^b   Lin, Lily ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CERUS CORPORATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; VIRUS DNA;

ARTICLE; DNA VIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; GENE AMPLIFICATION; HEPATITIS B VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PARVOVIRUS; PHOTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ULTRAVIOLET A RADIATION; VIRUS INACTIVATION;

DNA, VIRAL; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION; PSORALENS; TEMPLATES, GENETIC; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 33845403847     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509260     Document Type: Article

References (23)

1. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15:485-505.
2. Plentz A, Hahn J, Knoll A, Holler E, Jilg W, Modrow S. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion 2005; 45:1811-5.
3. Lefrere JJ, Servant-Delmas A, Candotti D, et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005; 106:2890-5.
4. Marchand S, Tchernia G, Hiesse C, et al. Human parvovirus B19 infection in organ transplant recipients. Clin Transplant 1999; 13:17-24.
5. Sheikh AU, Ernest JM. Clinical picture and consequences of fetal parvovirus B19 infection. Ann Med 1995; 27:7-8.
6. Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57:179-85.
7. Horowitz B, Ben-Hur E. Efforts in minimizing risk of viral transmission through viral inactivation. Ann Med 2000; 32:475-84.
8. Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39:228-30.
9. Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37:517-22.
10. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000; 40:1203-6.
11. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44:1496-504.
12. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45:580-90.
13. Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46:1168-77.
14. Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005; 45:1459-63.
15. Jauvin V, Alfonso RD, Guillemain B, Dupuis K, Fleury HJ. In vitro photochemical inactivation of cell-associated human T-cell leukemia virus type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005; 45:1151-9.
16. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx® technology. Semin Hematol 2001; 38:27-33.
17. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005; 15:269-76.
18. Schlente P. Protection against transfusion-associated graft-versus-host disease in blood transfusion: is gamma-irradiation the only answer? Transfus Med Hemother 2004; 31:24-31.
19. Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K. Dypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003; 47:475-9.
20. Roback ID, Conlan M, Drew WL, Ljungman P, Nichols WG, Preiksaitis JK. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006; 20:45-56.
21. Sawyer L, Hanson D, Dupuis K. Inactivation of parvovirus B19 in platelets by helinx technology. Transfusion 2004;44 (9S):102A.
22. Allain JP, Candotti D, Soldan K, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003; 101:2419-25.
23. Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004; 78:12169-78.